Immuron’s Travelan® Hits Record Global Sales
Company Announcements

Immuron’s Travelan® Hits Record Global Sales

Immuron (IMRN) has released an update.

Immuron Limited has announced a significant surge in global sales of its Travelan® product, with a record increase of 174% year-over-year, reaching AUD$4.9 million. The impressive sales performance is highlighted by a 223% rise in the Australian market and a noteworthy 74% growth in the U.S. for the financial year of 2024. Buoyed by these results, Immuron anticipates further growth through increased brand investment and distribution, especially in North America.

For further insights into IMRN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmuron reports Q3 sales of Travelan up 13% vs. Q2
TheFlyImmuron says NMRC completes interim analysis for evaluation in Campylobacter
TipRanks Auto-Generated NewsdeskImmuron’s Compliance Crucial: Sarbanes-Oxley Act Adherence Key to Financial Stability and Investor Trust
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App